Plasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD). The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver. A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G:A, 0.5%), was found in 3,469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+10% for D442G). However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations. The relative risk (RR) of CHD was 1.43 in men with mutations (P < .05); after adjustment for CHD risk factors, the RR was 1.55 (P = .02); after additional adjustment for HDL levels, the RR was 1.68 (P = .008). Similar RR values were obtained for the D442G mutation alone. Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg/dl; for HDL chol > 60 mg/dl men with and without mutations had low CHD prevalence. Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD prevalence in men with the D442G mutation and HDL cholesterol between 41 and 60 mg/dl. The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-atherogenicity of the HDL fraction.
S Zhong, D S Sharp, J S Grove, C Bruce, K Yano, J D Curb, A R Tall
Title and authors | Publication | Year |
---|---|---|
The emerging role of HDL in glucose metabolism
BG Drew, KA Rye, SJ Duffy, P Barter, BA Kingwell |
Nature Reviews Endocrinology | 2012 |
Utilizing imaging tools in lipidology: examining the potential of MRI for monitoring cholesterol therapy
XQ Zhao, WS Kerwin |
Clinical Lipidology | 2012 |
A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans
NC van de Pas, RA Woutersen, B Ommen, IM Rietjens, AA de Graaf |
Journal of lipid research | 2012 |
On- and Off-Target Pharmacology of Torcetrapib: Current Understanding and Implications for the Structure Activity Relationships (SAR), Discovery and Development of Cholesteryl Ester-Transfer Protein (CETP) Inhibitors
DG Johns, J Duffy, T Fisher, BK Hubbard, MJ Forrest |
Drugs | 2012 |
Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
MA Miyares, K Davis |
Vascular Health and Risk Management | 2012 |
Lipoproteins as biosensors of endothelial oxidative status
M Farkas-Epperson, NA Le |
Clinical Lipidology | 2012 |
Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
PM Katz, LA Leiter |
Canadian Journal of Cardiology | 2012 |
An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels
D Rhainds, BJ Arsenault, MR Brodeur, JC Tardif |
Future Cardiology | 2012 |
A Korean Family with Cholesterol Ester Transfer Protein Deficiency
SY Youn, IS Shin, YH Hong, DH Lee |
Journal of Genetic Medicine | 2012 |
Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors
A Escribano, AI Mateo, EM de la Nava, DR Mayhugh, SL Cockerham, TP Beyer, RJ Schmidt, G Cao, Y Zhang, TM Jones, AG Borel, SA Sweetana, EA Cannady, NB Mantlo |
Bioorganic & Medicinal Chemistry Letters | 2012 |
HDL functionality:
H Soran, S Hama, R Yadav, PN Durrington |
Current Opinion in Lipidology | 2012 |
Association of three polymorphisms of scavenger receptor class BI gene (exon8, exon1, intron5) with coronary stenosis in a coronary Tunisian population
J Rejeb, A Omezzine, I Boumaiza, L Rebhi, S Kacem, NB Rejeb, N Nabli, AB Abdelaziz, E Boughzala, A Bouslama |
Gene | 2012 |
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
GG Schwartz, AG Olsson, M Abt, CM Ballantyne, PJ Barter, J Brumm, BR Chaitman, IM Holme, D Kallend, LA Leiter, E Leitersdorf, JJ McMurray, H Mundl, SJ Nicholls, PK Shah, JC Tardif, RS Wright |
New England Journal of Medicine | 2012 |
HDL functionality in diabetes mellitus: potential importance of glycation
NN Younis, PN Durrington |
Clinical Lipidology | 2012 |
HDL-C: Does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies
R Gadi, A Amanullah, VM Figueredo |
International Journal of Cardiology | 2012 |
Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals
F Takeuchi, M Isono, T Katsuya, M Yokota, K Yamamoto, T Nabika, K Shimokawa, E Nakashima, T Sugiyama, H Rakugi, S Yamaguchi, T Ogihara, Y Yamori, N Kato |
PloS one | 2012 |
Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress
GJ Lyon, K Wang |
Genome Medicine | 2012 |
Papel de la proteína trasferidora de ésteres de colesterol en aterosclerosis: más preguntas que respuestas, más dudas que promesas
CG Santos-Gallego, JJ Badimón |
Revista Colombiana de Cardiología | 2012 |
Cholesteryl Ester Transfer Protein (CETP) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk
AC Papp, JK Pinsonneault, D Wang, LC Newman, Y Gong, JA Johnson, CJ Pepine, M Kumari, AD Hingorani, PJ Talmud, S Shah, SE Humphries, W Sadee, W Zhang |
PloS one | 2012 |